Investigating the Cryopreserved Blastocyst's ImplantatiOn Potential After Genetic Screening

An RCT Evaluating the Implantation Potential of Vitrified Embryos Screened by Next Generation Sequencing Following Trophectoderm Biopsy, Versus Vitrified Unscreened Embryos in Good Prognosis Patients Undergoing IVF

This is a two-arm parallel group randomized controlled trial at the Department of Reproductive Medicine at Ghent University Hospital. Women >=18 and <37 years of age undergoing their first or second IVF/ICSI treatment, with at least 2 good quality blastocysts remaining after fresh embryo transfer will be randomized to either transfer of a cryopreserved blastocyst selected based on morphology (standard treatment arm) or transfer of a cryopreserved blastocyst selected based on PGS and morphology (intervention treatment arm).

Inclusion Criteria:

• at least 2 blastocysts suitable for biopsy on day 5 of embryo development remaining after fresh transfer
• willing and able to give informed consent
• infertility as an indication for IVF/ICSI
• first or second IVF/ICSI cycle
• patients willing to accept single embryo transfer
• BMI range 18 to 35 kg/m2

Exclusion Criteria:

• any type of genetic abnormality or family history of genetic abnormality in subject or partner
• any other non-study related preimplantation genetic testing
• three or more clinical miscarriages (recurrent pregnancy loss, RPL)
• recurrent implantation failure (RIF): no positive β-hCG after transfer (fresh IVF/ICSI cycle or frozen) with no less than 6 cleavage stage embryos or no less than 4 blastocysts, all of good quality and of appropriate developmental stage
• severe endometriosis
• abnormal uterine cavity
• cycles requiring surgical sperm recovery procedures, total asthenozoospermia and/or globozoospermia
• treatment involving use of donor oocytes or use of gestational carrier